Treatment of Chronic Kidney Disease Stage 3

Introduction to CKD Stage 3 Management

The American Heart Association recommends that adults with CKD stage 3 should be treated with a comprehensive approach targeting blood pressure control (<130/80 mmHg), using ACE inhibitors or ARBs as first-line therapy, along with appropriate management of metabolic abnormalities and cardiovascular risk factors 1, 2, 3

Blood pressure should be maintained below 130/80 mmHg in all patients with CKD stage 3, as recommended by the American Heart Association 1, 2, 3
ACE inhibitors are the first-line treatment for hypertension in CKD stage 3, particularly in those with albuminuria (≥300 mg/d or ≥300 mg/g albumin-to-creatinine ratio) to slow kidney disease progression, according to the American Heart Association 3, 4
If ACE inhibitors are not tolerated, ARBs (such as losartan) may be used as an alternative, as suggested by the American Heart Association 2, 5

For patients with type 2 diabetes and CKD stage 3, the American Diabetes Association recommends that metformin can be used if eGFR is ≥45 mL/min/1.73 m² but should be used with caution and dose adjustment if eGFR is 30-45 mL/min/1.73 m² 6
SGLT2 inhibitors should be considered as they reduce CKD progression (RR 0.66, 95% CI 0.58-0.75) and heart failure hospitalizations (RR 0.64, 95% CI 0.54-0.77), as recommended by the American College of Cardiology 7
GLP-1 receptor agonists are beneficial for cardiovascular protection and may slow CKD progression, according to the American Diabetes Association 6, 7

Regular monitoring for common complications of CKD stage 3 should include electrolyte abnormalities (particularly potassium), metabolic acidosis, anemia (hemoglobin and iron studies), and metabolic bone disease (calcium, phosphate, PTH, vitamin D), as recommended by the American Diabetes Association 6

Dose adjustment is necessary for many medications cleared by the kidneys, according to the National Kidney Foundation 8
For patients requiring contrast studies, preventive measures should be taken, including hydration with normal saline before contrast administration, use of low-osmolar or iso-osmolar contrast media, and minimizing contrast volume, as recommended by the European Society of Cardiology 9

Regular monitoring of kidney function (eGFR and albuminuria) every 6-12 months is recommended by the American Diabetes Association 6
Assessment of blood pressure at each clinical visit is recommended by the American Diabetes Association 6
Laboratory evaluations for CKD-related complications every 6-12 months are recommended by the American Diabetes Association 6
Adjustment of medication dosages as kidney function changes is necessary, according to the National Kidney Foundation 8

In patients with heart failure and CKD, diuretics should be prescribed for volume overload, followed by ACE inhibitors or ARBs and beta-blockers, as recommended by the American Heart Association 1, 5